JP6910800B2 - Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療 - Google Patents

Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療 Download PDF

Info

Publication number
JP6910800B2
JP6910800B2 JP2016573772A JP2016573772A JP6910800B2 JP 6910800 B2 JP6910800 B2 JP 6910800B2 JP 2016573772 A JP2016573772 A JP 2016573772A JP 2016573772 A JP2016573772 A JP 2016573772A JP 6910800 B2 JP6910800 B2 JP 6910800B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
gdf15
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016573772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519765A (ja
JP2017519765A5 (enExample
Inventor
ジュリス，ジェノ
ラーナー，ロレーナ
Original Assignee
アベオ ファーマシューティカルズ， インコーポレイテッド
アベオ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アベオ ファーマシューティカルズ， インコーポレイテッド, アベオ ファーマシューティカルズ， インコーポレイテッド filed Critical アベオ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2017519765A publication Critical patent/JP2017519765A/ja
Publication of JP2017519765A5 publication Critical patent/JP2017519765A5/ja
Application granted granted Critical
Publication of JP6910800B2 publication Critical patent/JP6910800B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016573772A 2014-06-20 2015-06-19 Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療 Active JP6910800B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015093P 2014-06-20 2014-06-20
US62/015,093 2014-06-20
PCT/US2015/036790 WO2015196142A1 (en) 2014-06-20 2015-06-19 Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020105424A Division JP2020147609A (ja) 2014-06-20 2020-06-18 Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療

Publications (3)

Publication Number Publication Date
JP2017519765A JP2017519765A (ja) 2017-07-20
JP2017519765A5 JP2017519765A5 (enExample) 2018-07-26
JP6910800B2 true JP6910800B2 (ja) 2021-07-28

Family

ID=53724442

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016573772A Active JP6910800B2 (ja) 2014-06-20 2015-06-19 Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
JP2020105424A Pending JP2020147609A (ja) 2014-06-20 2020-06-18 Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020105424A Pending JP2020147609A (ja) 2014-06-20 2020-06-18 Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療

Country Status (4)

Country Link
US (3) US20170137505A1 (enExample)
EP (1) EP3157952B1 (enExample)
JP (2) JP6910800B2 (enExample)
WO (1) WO2015196142A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100689A1 (en) 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
EP4005585B1 (en) 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
CA2956256A1 (en) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
JP2020503842A (ja) * 2016-10-12 2020-02-06 ヤンセン バイオテツク，インコーポレーテツド Ｇｄｆ１５様生物活性の調節因子をスクリーニングするための方法
KR102715542B1 (ko) 2018-08-20 2024-10-08 화이자 인코포레이티드 항-gdf15 항체, 조성물 및 사용 방법
JP2024541933A (ja) 2021-11-02 2024-11-13 ファイザー・インク 抗ｇｄｆ１５抗体を使用してミトコンドリア筋症を処置する方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5733254A (en) 1987-10-15 1998-03-31 Cypress Bioscience, Inc. Method for treating patients suffering from immune thrombocytopenic purpura
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
AU2002257420A1 (en) 2001-05-01 2002-11-11 National Research Council Of Canada A system for inducible expression in eukaryotic cells
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7157235B2 (en) * 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
ES2555956T3 (es) * 2004-04-13 2016-01-11 St Vincent's Hospital Sydney Limited Método para modular el apetito
CA2660691C (en) * 2006-08-04 2020-01-14 Medizinische Hochschule Hannover Means and methods for assessing the risk of cardiac interventions based on gdf-15
WO2009021293A1 (en) * 2007-08-16 2009-02-19 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
JP2011502106A (ja) * 2007-10-09 2011-01-20 セントビンセンツ ホスピタル シドニー リミテッド マクロファージ阻害性サイトカイン−１を除去又は不活性化して悪液質を治療する方法
TR201802772T4 (tr) * 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2014100689A1 (en) * 2012-12-21 2014-06-26 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies

Also Published As

Publication number Publication date
US20220403015A1 (en) 2022-12-22
EP3157952B1 (en) 2021-12-22
WO2015196142A1 (en) 2015-12-23
JP2020147609A (ja) 2020-09-17
JP2017519765A (ja) 2017-07-20
EP3157952A1 (en) 2017-04-26
US20170137505A1 (en) 2017-05-18
US20190292251A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
JP6910800B2 (ja) Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
JP2025143268A (ja) 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤
US20240262926A1 (en) Fusion Protein Containing BDNF
US11897948B2 (en) Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator
JP7512272B2 (ja) Ａｌｋ２抗体及びその使用方法
RU2656162C2 (ru) Антитела к интерлейкину 6 и их применение
JP5068253B2 (ja) 心臓血管疾患の治療
JP2017503022A (ja) インビボで細胞に活性型テロメラーゼを提供する組成物および方法
JP6198742B2 (ja) 肺高血圧症
WO2022240948A1 (en) Methods of using alk2 and alk3 antibodies
EP3211004A1 (en) Use of macrophage inflammatory protein-1 (mip-1 ) inhibitor for improving tissue ischemia and diabetes vasculopathy by promoting angiogenesis
CA3184349A1 (en) Compositions and methods for treating allograft vasculopathy, moyamoya disease, moyamoya syndrome and intimal proliferation
WO2024011946A1 (en) Polypeptide dimers for the treatment of systemic sclerosis
EA042620B1 (ru) Лечение хронического заболевания почек и другого нарушения функции почек при помощи модулятора gdf15
BR112016029820B1 (pt) Uso de um anticorpo anti-gdf15 para a preparação de uma composição e/ou medicamento para no tratamento de doença renal crônica e outras disfunções renais
RU2795320C2 (ru) Терапевтическое средство для лечения кардиомиопатии, перенесенного инфаркта миокарда и хронической сердечной недостаточности
US20220096563A1 (en) Composition for treating inflammatory disease induced by hyperimmune response
Winter et al. 1206 Endothelial cell-specific deletion of vascular endothelial growth factor receptor 2/kinase insert domain protein receptor and proliferative pulmonary vasculopathy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191008

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200618

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200618

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200630

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200806

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200807

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200828

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200901

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210330

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210517

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210615

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210615

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210707

R150 Certificate of patent or registration of utility model

Ref document number: 6910800

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250